21 results about "Enolase" patented technology

The present invention relates to a non-invasive test for the detection of deep endometriosis. Particularly, although not exclusively, aspects of the present invention relate to one or more glycolysis-associated biomarkers (e.g., phosphoglycerate mutase 1 (PGAM1), Enolase-1 (ENO1), phosphofructokinase-1 (PFKP) and / or Hexokinase) and / or cytokines associated with aerobic glycolysis (e.g., IL-6 and / or TGF-β) which can be used to determine the likelihood of a subject having deep endometriosis based on a sample obtained from the subject.

To provide an estimation method for estimating the amount of marker proteins in the stratum corneum. [Solution] Identify one or more cell regions, stratified exfoliation regions, and single-cell regions in the stratum corneum image. A marker protein quantity estimation method that estimates the amount of marker proteins in the stratum corneum from stratum corneum images based on the correlation between the obtained stratum corneum parameters as explanatory variables and one of the following as the dependent variable: Enolase-1 quantity, FABP5 quantity, or Polyamine quantity.

The invention discloses a biomarker combination related to hypoxia-induced neuroinflammation and application of the biomarker combination, and belongs to the technical field of biomarker detection. The marker combination disclosed by the invention consists of serum S100 beta protein, neuron-specific enolase, interleukin-6, high-mobility group protein B1 and neurofilament light-chain protein. The marker combination can be used for stratification of nervous system injury risk of severe hypoxia patients and acquisition of prognosis evaluation data. According to the detection method disclosed by the invention, synchronous quantitative detection of five markers is realized by adopting a multiple immunofluorescent microsphere technology, and a marker combination scoring algorithm is established to comprehensively evaluate the severity of the hypoxia-related neuroinflammation.

The invention belongs to the technical field of bioinformatics and medical detection, and particularly relates to a marker combination for neuroblastoma (NB) noninvasive risk level grading, a prediction model, a prediction method and application thereof. The marker combination is used for determining the sex, determining whether the month age is greater than 18 months, determining whether plasma MYCN is amplified, determining whether tumors are metastatic, and determining the content of neuron-specific enolase and lactic dehydrogenase; a machine learning algorithm is used for constructing an NB noninvasive risk degree grading prediction model, the comprehensive performance of the random forest model is optimal, the area value under a subject working characteristic curve reaches 0.956, the sensitivity is 92.9%, the specificity is 82.1%, the accuracy rate is 87.5%, the Kappa value is 0.75, the F1 score is 0.881, and NB middle and low risk patients and NB high risk patients can be effectively distinguished; the NB non-invasive risk level grading prediction model constructed by the invention can quickly, accurately and non-invasively perform NB risk level grading, and has a relatively good clinical application value.

This application discloses a method for determining the standard value of neuron-specific enolase (NSE) solution, belonging to the field of biotechnology. The determination method provided in this application includes characterizing the physicochemical properties of the NSE standard candidate solution, such as purity, molecular weight, secondary structure, and bioactivity; diluting and dispensing the NSE standard candidate solution; accurately determining the content of the NSE standard candidate solution and verifying its homogeneity and stability using isotope dilution mass spectrometry based on amino acid analysis and characteristic peptide analysis; and evaluating the uncertainty of the NSE solution standard value determination results. The determination method provided in this application has good reliability and accuracy, and the determination results are traceable to SI units (mol).

The invention discloses deoxyribozyme targeting enolase 1 and application of deoxyribozyme in preparation of a gene medicine for treating rheumatoid arthritis, and belongs to the technical field of biology. On the basis of a mouse ENO1 mRNA secondary structure, 15 deoxyribozyme is designed and screened, Dz8 has the strongest ENO1 mRNA cutting capacity, and the expression level of the gene can be effectively reduced; meanwhile, the Dz8 has Mg-dependent efficient ENO1 mRNA cleavage activity and time-dependent multi-turnover kinetic characteristics, ENO1 expression can be remarkably inhibited at the gene and protein levels, then inflammatory factor secretion is reduced, the glycolysis level is regulated and controlled, and the Dz8 has important application prospects in the field of rheumatoid arthritis gene therapy. The invention provides a new target and a treatment strategy for rheumatoid arthritis gene therapy, and Dz8 is expected to become a potential tool for rheumatoid arthritis gene therapy.

The present invention provides methods and uses for treating or preventing fibrosis and fibrotic diseases, including administering a composition containing an enolase inhibitor such as POMHEX.

Provided are identifies new methods for regulating (or reprogramming) glycolytic reaction by using alpha-enolase (ENO-1) antagonist or agonist. More specifically, provided are methods for glycolysis reprogramming by targeting extracellular ENO-1 or membrane-associated ENO-1.

The invention relates to application of pyruvate kinase (PKM), triosephosphate isomerase (TPI1), alpha-enolase (ENO1) and lactic dehydrogenase (LDHB) in urine in preparation of medicines for exercise function evaluation (exercise intensity, exercise density, exercise duration, exercise function, exercise posture and physiological state), exercise risk prediction, exerciser physique evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise function evaluation, exercise and scientific exercise guidance, exercise scheme screening and other reagents are applied. Research proves that the proteins PKM, TPI1, ENO1 and LDHB in urine are key proteins for exercise training monitoring for the first time. Compared with the prior art, the expression of the four proteins in a urine sample after movement is obviously increased. The sensitivity and the specificity of various purposes such as function evaluation, exercise risk prediction and scientific exercise guidance of exercise training can be improved through independent use of one of the components and combined use of multiple components.

The invention discloses a gastric cancer biomarker ENO3 and a detection reagent thereof, belongs to the technical field of biological medicines, and particularly relates to a detection reagent of a gastric cancer marker. The detection reagent comprises an upstream primer and a downstream primer of a gastric cancer marker, and modified immunomagnetic beads, the gastric cancer marker is enolase 3. The invention finds and verifies that the gastric cancer marker enolase 3 promotes malignant transformation of gastric cancer by promoting glycolysis of gastric cancer cells, activating a WNT / beta-catenin signal channel and up-regulating expression of matrix metalloproteinase at the same time; meanwhile, by optimizing an immunomagnetic bead structure targeting the marker, the capture efficiency of the marker on trace tumor cells in peripheral blood is improved, so that the signal intensity of subsequent marker detection is enhanced, and an important tool is provided for improving the positive detection rate of gastric cancer detection based on the peripheral blood.

Pharmaceutical compositions and methods for using boron-based ligands of enolases to treat cancer are disclosed. One such pharmaceutical composition includes a therapeutically effective amount of a ligand of enolase (1) having a general formula III or a pharmaceutically acceptable derivative thereof. The cancer can be a carcinoma, sarcoma, lymphoma, leukemia, or melanoma. The cancer can be prostate cancer.

The present invention provides a novel antibody fragment based antifungal conjugate selectively targeting Candida spp. comprising of at least one antimicrobial peptide at one end of the conjugate, more particularly, human Histatin-5; an antibody fragment at the other end of the conjugate, specific against Candida spp. enolase, a virulence factor protease and biofilm specific antigen of Candida spp.; at least one signal protease cleavage sequence susceptible to cleavage by virulent protease secreted by Candida spp., secreted aspartyl proteinase-1 (SAP1); and at least one flexible polypeptide linker. The signal protease cleavage sequence and the flexible polypeptide linker are in tandem with each other and placed in between the antimicrobial peptide and the antibody. The in vitro MIC-99 of the conjugate against Candida spp., is in the range of 0.2-0.3 μM, more specifically, 0.25 μM or 250 nM.

Provided herein are methods for treating an angiogenesis-related disease comprising administration to a subject in need thereof an effective amount of alpha-enolase (enolase-1, ENO-1) antagonist.

To provide an estimation method for estimating the amount of marker proteins in the stratum corneum. [Solution] Identify one or more cell regions, stratified exfoliation regions, and single-cell regions in the stratum corneum image. A marker protein quantity estimation method that estimates the amount of marker proteins in the stratum corneum from stratum corneum images based on the correlation between the obtained stratum corneum parameters as explanatory variables and one of the following as the dependent variable: Enolase-1 quantity, FABP5 quantity, or Polyamine quantity.

The invention discloses an application of a hyperbaric oxygen-induced sodium channel active marker in epilepsy susceptibility evaluation. Belongs to the technical field of biomedicine. In the application, a sodium channel active marker comprises peripheral blood sodium channel protein, peripheral blood phosphorylated sodium channel protein, neuron-specific enolase, S100B protein and epilepsy discharge frequency. The high-pressure oxygen induction condition is that the pressure is increased to 2.0 absolute atmospheric pressure within 15 min, then pure oxygen is absorbed for 1 h under the stable pressure condition, and finally the pressure is reduced to normal pressure at a constant speed within 15 min. The method has the advantages of being high in evaluation accuracy and small in harm to human bodies, and the problem that in the prior art, epilepsy susceptible high-risk groups cannot be screened is effectively solved.

The problem that this invention aims to solve is to provide a Corynebacterium glutamicum mutant strain with improved L-lysine production ability, and a method for producing L-lysine using the mutant strain. [Solution] The present invention relates to a Corynebacterium glutamicum mutant strain with improved L-lysine production ability and a method for producing L-lysine using the same. The Corynebacterium glutamicum mutant strain can increase the supply of precursors and increase sugar utilization, thereby improving the L-lysine production yield, by increasing or enhancing the expression of genes that encode enolase, or simultaneously decreasing or weakening the expression of gluconate operon transcription repressors.

The invention provides a combined marker combination as well as a detection method and a kit thereof. The combined marker combination comprises a plasma protein marker and a blood metabolism marker, the plasma protein marker comprises an adaptor protein PH-containing structural domain, enolase 3, a proline 4-hydroxylase alpha1 chain and ethanol dehydrogenase 1C, and the adaptor protein comprises an adaptor protein PH-containing structural domain, a proline 4-hydroxylase alpha1 chain and a proline 4-hydroxylase alpha2 chain. The blood metabolism marker is prepared from diosgenin, eicosapentaenoic acid, folinic acid, hydroxyprogesterone hexanoate, testosterone, perfluorooctane sulfonic acid, prasterone sulfate, androstane dienone, long pine needle ketone and 1-(22 carbon 4 enoyl) lysophosphatidylcholine. Through cooperative detection of protein-metabolism markers and combined application of a machine learning model, accurate prediction of the age-related disease risk is achieved, the cognitive decline risk can be pre-judged in advance, meanwhile, efficient synchronous detection of multiple markers is achieved by means of a liquid chromatography-tandem mass spectrometry synchronous detection technology, the sample dosage is small, the detection process is standardized, and the detection efficiency is high. The large-scale queue research requirement is met, and multi-center clinical application and popularization are facilitated.

A coupled tethered enzyme luminescence assay for measuring the amount of enzymatic activity of neural specific enolase in a liquid blood sample taken from a patient. The assay has a test well and a positive control well. The test well has a number of components including an inhibitor and a number of first tethered enzyme nanobots formed by tethering pyruvate kinase enzyme to silica nanoparticles, and a number of second enzyme nanobots formed by tethering luciferase molecules to silica nanoparticles for oriented immobilization of the tethered enzymes pyruvate and luciferase. The pyruvate kinase and luciferase enzymes have two differing types of affinity tags. One type of affinity tag facilitates extraction of enzymes from a liquid and another affinity tag for tethering to a silica nanoparticle. The positive control well includes the components of the test well and an added preset amount of enolase enzyme.